GENEVA—Reviews of CD8-positive T-cell infiltration as an independent prognostic biomarker in resected non-small cell lung cancer, and the potential of checkpoint inhibitor therapy for mesothelioma after first or second line chemotherapy were presented at the European Lung Cancer Conference by Martin Reck MD PhD, from the Lung Clinic Grosshansdorf in Germany. He discussed the clinical implications with Oncology Times reporter Peter Goodwin.
You may also like...
Time from nephrectomy to metastasis confirmed as prognostic in patients with renal cell carcinoma treated with targeted therapies 13 Feb, 2014 Which Tasks Most Influence Pediatric PT Productivity, Effectiveness? 31 Dec, 2019 Low risk prostate cancer: less treatment means lower cost, and better patient outcomes 16 Mar, 2013 Growing Evidence that Anti BRAF Melanoma Drugs Benefit Some Patients with Non-Small Cell Lung Cancer 27 Apr, 2015
- Previous story Prior Chemotherapy: No Bar to Checkpoint Inhibition in Mesothelioma
- Next story New Drug for Patients with EGFR-TKI-resistant Advanced Non-Small Cell Lung Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014